Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PTPRC | P08575 | 3/20 | 0.49 |
| ▸ | S100A4 | P26447 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | MAX | P61244 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11647394 | 0.88 | PTGS2 (0.57) | PTGS2POLBRAB9APTPRCS100A4 | |
| SCHEMBL11667865 | 0.87 | PTPRC (0.55) | PTPRCS100A4BCHEACHECES1 | |
| SCHEMBL9706699 | 0.85 | NT5E (0.51) | PTGS2POLBRAB9APTPRCS100A4 | |
| SCHEMBL3617230 | 0.84 | PTGS2 (0.57) | PTGS2POLBRAB9APTPRCS100A4 | |
| SCHEMBL8820272 | 0.84 | PTGS2 (0.57) | PTGS2POLBRAB9APTPRCS100A4 | |
| SCHEMBL11647391 | 0.81 | LMNA (0.48) | PTGS2POLBPTPRCS100A4BCHE | |
| SCHEMBL2009412 | 0.80 | ALDH1A1 (0.55) | RAB9APTPRCMAPTALDH1A1MEN1 | |
| SCHEMBL8820656 | 0.80 | PTGS2 (0.49) | PTGS2POLBRAB9APTPRCS100A4 | |
| SCHEMBL9798213 | 0.79 | PTGS2 (0.55) | PTGS2POLBRAB9APTPRCS100A4 | |
| SCHEMBL8382506 | 0.78 | POLB (0.64) | PTGS2POLBRAB9APTPRCS100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | PTGS2 483/4885POLB 1554/4885RAB9A 3864/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | PTGS2 483/4885POLB 1554/4885RAB9A 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.